Optineurin缺失通过棕榈酰化依赖的IFNGR1溶酶体分选降解驱动结直肠癌免疫逃逸
该研究探讨结直肠癌中IFN与MHC信号通路的完整性,发现Optineurin是两个通路的共享节点并预测患者预后。Optineurin缺失在早期结直肠癌中即出现,可减弱IFNGR1和MHC-I表达、损害T细胞免疫并降低免疫治疗疗效。机制上,IFNGR1在Cys122位点发生S-棕榈酰化,AP3D1结合并分选棕榈酰化IFNGR1至溶酶体降解,而Optineurin与AP3D1互作阻止该过程,从而维持IFNγ和MHC-I信号完整性;药物靶向IFNGR1棕榈酰化可稳定IFNGR1、增强肿瘤免疫并增敏检查点治疗。
要点
- Optineurin缺失见于早期结直肠癌,可预测患者预后。
- Optineurin缺失减弱IFNGR1和MHC-I表达,损害T细胞免疫。
- 靶向IFNGR1棕榈酰化可稳定IFNGR1并增敏检查点治疗。
核心结论
- Optineurin缺失通过棕榈酰化依赖的IFNGR1溶酶体分选和降解损害IFNγ与MHC-I信号完整性,驱动结直肠癌免疫逃逸和固有免疫治疗抵抗。
研究设计与样本
- 研究在人结直肠癌组织、小鼠癌症模型和癌症患者中探索IFN与MHC信号通路的完整性。
主要发现
- Optineurin是IFN和MHC信号通路的共享节点,并预测结直肠癌患者结局。
- Optineurin缺失在早期人结直肠癌中即出现,可减弱IFNGR1和MHC-I表达、损害T细胞免疫并降低免疫治疗疗效。
- IFNGR1在Cys122位点发生S-棕榈酰化,AP3D1结合并分选棕榈酰化IFNGR1至溶酶体降解。
- Optineurin与AP3D1互作,阻止棕榈酰化IFNGR1的溶酶体分选和降解,维持IFNγ和MHC-I信号完整性。
- 药物靶向IFNGR1棕榈酰化可稳定IFNGR1、增强肿瘤免疫并增敏检查点治疗。
临床怎么用
- Optineurin缺失可作为结直肠癌免疫逃逸和固有免疫治疗抵抗的潜在生物标志物。
- 药物靶向IFNGR1棕榈酰化可能稳定IFNGR1、增强T细胞免疫并增敏检查点治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in IFN and MHC signaling genes endow immunotherapy resistance. Patients with colorectal cancer infrequently exhibit IFN and MHC signaling gene mutations and are generally resistant to immunotherapy. In exploring the integrity of IFN and MHC signaling in colorectal cancer, we found that optineurin was a shared node between the two pathways and predicted colorectal cancer patient outcome. Loss of optineurin occurs in early-stage human colorectal cancer. Immunologically, optineurin deficiency was shown to attenuate IFNGR1 and MHC-I expression, impair T-cell immunity, and diminish immunotherapy efficacy in murine cancer models and patients with cancer. Mechanistically, we observed that IFNGR1 was S-palmitoylated on Cys122, and AP3D1 bound with and sorted palmitoylated IFNGR1 to lysosome for degradation. Unexpectedly, optineurin interacted with AP3D1 to prevent palmitoylated IFNGR1 lysosomal sorting and degradation, thereby maintaining IFNγ and MHC-I signaling integrity. Furthermore, pharmacologically targeting IFNGR1 palmitoylation stabilized IFNGR1, augmented tumor immunity, and sensitized checkpoint therapy. Thus, loss of optineurin drives immune evasion and intrinsic immunotherapy resistance in colorectal cancer. SIGNIFICANCE: Loss of optineurin impairs the integrity of both IFNγ and MHC-I signaling pathways via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation, thereby driving immune evasion and intrinsic immunotherapy resistance in colorectal cancer. Our work suggests that pharmacologically targeting IFNGR1 palmitoylation can stabilize IFNGR1, enhance T-cell immunity, and sensitize checkpoint therapy in colorectal cancer.See related commentary by Salvagno and Cubillos-Ruiz, p. 1623.This article is highlighted in the In This Issue feature, p. 1601.
引用
- Du W, Hua F, Li X, et al. Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. Cancer Discov. 2021. PMID: 33627378. doi:10.1158/2159-8290.CD-20-1571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。